Week of Jan. 30, 2012: Amgen Agrees to Micromet for $1.16 Billion; Cephalon Issues Recall of Treanda; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Jan. 30, 2012: Amgen Agrees to Micromet for $1.16 Billion; Cephalon Issues Recall of Treanda; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company Notes

Amgen has agreed to acquire the biotechnology company Micromet for approximately $1.16 billion ($11 per share in cash). The transaction was unanimously approved by both companies’ boards of directors and includes blinatumomab, a bispecific T-cell engager (BiTE) antibody in Phase II clinical development for treating acute lymphoblastic leukemia and non-Hodgkin’s lymphoma, as well as proprietary BiTE antibody technology. Read More

Catalent Pharma Solutions has expanded its controlled-release drug-development and supply capabilities at its Schorndorf, Germany, facility. The expansion includes the addition of R&D and commercial-scale fluid–bed technology, OptiMelt hot-melt extrusion capabilities, and additional cGMP compliance for handling OEB Class III customer products. Read More

Celgene, a biopharmaceutical company, has agreed to acquire the clinical-stage biotechnology company Avila Therapeutics for up to $925 million. The acquisition provides Celgene with Avila’s AVL-292, a highly selective Bruton’s tyrosine kinase (Btk) inhibitor for treating hematologic cancers, currently in Phase I clinical development. In addition, Avila’s proprietary Avilomics platform, which is used to produce covalent drugs that achieve protein silencing. Read More

Kerry Ingredients & Flavors, a provider of functional ingredients, is investing $10 million in expanding its Beloit, Wisconsin, facility to include a cell-science laboratory. The expansion will feature a consumer nutrition center, flavor laboratories, and product ideation and customer collaboration suites. The project is expected to be complete by August 2012, and will add an additional 30,000 ft2 to the existing 260,000-ft2 facility. Read More

Teva Pharmaceutical Industries’s subsidiary Cephalon has issued a voluntary recall of Treanda (bendamustine hydrochloride) for injection (25mg/8mL), lot TB30111), for treating indolent B-cell non-Hodgkin’s lymphoma, after glass fragments were discovered in a single vial. The affected Treanda lot is packaged in 8-mL vials and was distributed to wholesalers and distributors nationwide between Mar. 22, 2011, and Oct. 5, 2011. Read More

Industry Briefs:

A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here